The purpose of this study is to utilize this technology in the early detection and staging of pathologic states within prostate cancer patients using the information obtained on mpMRI and serum biomarkers from the patient's blood (if collected). Ultimately, investigators hope to improve the diagnostic accuracy and treatment selection process for these patients. Applying the fusion software which adds mpMRI to ultrasound images in real time, to an otherwise clinically standard but non-targeted ultrasound-guided prostate biopsy procedure will help with accurate and early diagnosis of prostate cancer.
Able to give informed consent Male - age > 18 mpMRI within the previous 6 months (PIRADS 3,4,5, all stages of PCa) Scheduled for TRUS biopsy for prostate lesion or mass
Exclusion Criteria:
Age under 18 years of age. Female Pre-existing blood dyscrasias Inability to perform TRUS due to anal sphincter closure/surgery Patients needing general anesthesia Patients allergic to lidocaine Patients allergic or unable to take antibiotics
